HOSPIRA INC | 27,251 Euro | +0,044 +0,16 % | |
| WKN: A0CAGX ISIN: US4410601003 Ticker-Symbol: HOS | Frankfurt | 19.06.13 | 08:03 Uhr |
Branche GesundheitswesenAktienmarkt S&P 500 |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 18.06. | Lowest Projected Earnings Growth in the Pharmaceuticals Industry Detected in Shares of Hospira | - | SmarTrend | |
| 06.06. | Hospira: A Case Study For Strategic Valuation | - | Seeking Alpha | |
| 04.06. | Hospira-Daten zum europäischen Epoetin-Biosimilar Retacrit bestätigen dessen Ansprechen und Verträglichkeit bei der Behandlung von Anämie als Begleiterscheinung der Chemotherapie | 102 | news aktuell | |
| - Anwendungsbeobachtung mit über 2.300 Patienten im Zuge der ASCO vorgestellt - Lake Forest, Illinois (ots/PRNewswire) - Hospira, Inc. [http://www.hospira.com/] , der weltweit führende Anbieter... Mehr lesen zu: Hospira-Daten zum europäischen Epoetin-Biosimilar Retacrit bestätigen dessen Ansprechen und Verträglichkeit bei der Behandlung von Anämie als Begleiterscheinung der Chemotherapie | ||||
| 03.06. | Hospira Reveals Positive Results From Post-marketing Study Of Retacrit | 80 | AFX News | |
| WASHINGTON (dpa-AFX) - Hospira Inc. (HSP), a provider of injectable drugs
and infusion technologies, on Monday revealed positive results from a
post-marketing study of its European biosimilar... Mehr lesen zu: Hospira Reveals Positive Results From Post-marketing Study Of Retacrit | ||||
| 03.06. | UPDATE: Hospira Data on European Biosimilar Epoetin, Retacrit Affirm Treatment Response, Says Study Met Primary Endpoint | - | Benzinga.com | |
| 03.06. | Hospira (HSP) Retacrit Met Primary Endpoint in Post-Marketing Study | - | StreetInsider.com | |
| 03.06. | Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy | 61 | PR Newswire | |
| LAKE FOREST, Ill., June 3, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today results from a post-marketing... Mehr lesen zu: Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy | ||||
| 31.05. | Another Day, Another Warning Letter For Hospira, But Will The FDA Issue A Consent Decree? | 1 | Forbes | |
| 31.05. | Relatively Low Future Earnings Growth Detected in Shares of Hospira in the Pharmaceuticals Industry | - | SmarTrend | |
| 31.05. | US drug regulator detects lapses in Hospira's TN unit | - | Times of India | |
| 30.05. | FDA raises drug safety concerns at Hospira facility in India | 1 | Reuters.com | |
| 30.05. | Hospira (HSP) Receives FDA Warning Letter for Irungattukottai Facility | 1 | StreetInsider.com | |
| 30.05. | HOSPIRA INC - 8-K, Current Report | - | SEC Filings | |
| 28.05. | Back to Neutral on Hospira | 1 | Zacks | |
| 23.05. | Hospira Crosses Below its 10-day MA | 1 | SmarTrend | |
| 21.05. | Duly Noted: Metra cops' pay, Hospira patent dispute, history of tornados in Chicago | - | bizjournals | |
| 21.05. | U.S. court ruling favors Cubist in patent case versus Hospira | 1 | Reuters.com | |
| 21.05. | U.S. court ruling favors Cubist in patent case vs Hospira | 2 | Reuters.com | |
| 20.05. | Hospira Earnings In Retrospect: Up 11.3% in the Last 19 Days | - | SmarTrend | |
| 14.05. | Hospira Reappoints Dr. Sumant Ramachandra Chief Scientific Officer | 23 | PR Newswire | |
| LAKE FOREST, Ill., May 14, 2013 /PRNewswire/ --Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Sumant Ramachandra, M.D.... Mehr lesen zu: Hospira Reappoints Dr. Sumant Ramachandra Chief Scientific Officer | ||||
Seite: 1 2 3 4 5 ... Weiter >>
118 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| DAVITA | 95,37 | -1,98 % | Iconix Brand Group, Ralph Lauren, DaVita HealthCare Partners, Myriad Genetics and Biogen Idec highlighted as Zacks Bull and Bear of the Day |
| RHOEN-KLINIKUM | 17,385 | -0,83 % | wikifolio-Trader kaufen Praktiker und Commerzbank, kommentieren Rhön Klinikum und CTS |
| FRESENIUS MEDICAL CARE | 53,04 | -0,30 % | dpa-AFX Überblick: ANALYSTEN-EINSTUFUNGEN vom 14.06.2013: LUFTHANSA, RWE, VOLKSWAGEN, BMW, DAIMLER, DIALOG SEMICONDUCTOR, ENEL, RHOEN-KLINIKUM, CONTINENTAL, FRAPORT, GOOGLE, CTS EVENTIM, HEIDELBERGER ... |
| MEDTRONIC | 39,401 | -0,56 % | Medtronic Infuse study a sign of more 'open science' to come? |
| MCKESSON | 86,39 | +1,72 % | XFRA DIVIDEND INFORMATION - 05.06.2013 - 1 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von